Beranda › Cedera Ginjal Akut
Uji klinis Cedera Ginjal Akut yang merekrut di AS
49 studi untuk Cedera Ginjal Akut merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Cincinnati, OH8 studi
- Birmingham, AL8 studi
- Dallas, TX7 studi
- Durham, NC7 studi
- Baltimore, MD7 studi
- Ann Arbor, MI7 studi
- San Francisco, CA7 studi
- New York City, NY6 studi
- Cleveland, OH6 studi
- Boston, MA5 studi
- Pittsburgh, PA5 studi
- Houston, TX5 studi
- Atlanta, GA5 studi
- Detroit, MI5 studi
- Charleston, SC5 studi
- Rochester, MN4 studi
- Chicago, IL4 studi
- Nashville, TN4 studi
- New Haven, CT3 studi
- Seattle, WA3 studi
- Davie, FL3 studi
- Philadelphia, PA3 studi
- Washington, DC3 studi
- Winston-Salem, NC3 studi
- Louisville, KY3 studi
- The Bronx, NY3 studi
- Los Angeles, CA3 studi
- Columbus, OH3 studi
- Salt Lake City, UT3 studi
Berdasarkan negara bagian
- Alabama8 studi
- Arizona3 studi
- California12 studi
- Colorado4 studi
- Connecticut3 studi
- Florida8 studi
- Georgia5 studi
- Illinois4 studi
- Kentucky4 studi
- Maryland8 studi
- Massachusetts5 studi
- Michigan10 studi
- Minnesota5 studi
- New York8 studi
- North Carolina9 studi
- Ohio11 studi
- Pennsylvania8 studi
- South Carolina5 studi
- Tennessee5 studi
- Texas11 studi
- Utah3 studi
- Virginia5 studi
- Washington3 studi
- Wisconsin3 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Infliximab for Immune Checkpoint Inhibitor Associated AKI
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07683975A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05805709Nicotinamide Mononucleotide in Patients Undergoing Cardiac Surgery
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07013591Improving Preterm Kidney Outcomes With Caffeine
Menerima pesertaFase 2
12 Hours – 96 Hours · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07262060Impact of Intraoperative Oxygenation Practices on Patient Outcomes
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07224243Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT05758077A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07734636A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07215702Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT06937307The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07556107Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT06699849A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health Intervention
Menerima peserta
Usia 1 hingga 18 · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT04403633Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT07016074Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05399537Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy
Menerima pesertaFase 2
Hingga usia 18 · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT07212595FST Analysis Supporting Timely Therapy and Risk Assessment Via Clinical Decision Support for Kids
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT07718464LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT06446739Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Jun 2026 · NCT07670520The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Mei 2026 · NCT06802224Ultra-Low Contrast Angiography in AKI
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT05906758Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
Menerima peserta
9 Months – 21 Years · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT05219110QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
Menerima pesertaStudi observasional
Hingga usia 22 · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT06517810Kidney Function in People With Cystic Fibrosis in the Era of HEMT
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 7 ke atas · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT06595420Acute Normovolemic Hemodilution on Urine Neutrophil Gelatinase-associated Lipocalin Levels
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 1 Mei 2026 · NCT05349292Effectiveness-Implementation Evaluation of Acute Kidney Injury Decision Support
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Apr 2026 · NCT06840210Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.